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Abstract  
 
Aims – To assess the proportion of patients achieving undetectable viral loads (<50 copies/mL) within 6 
and 12 months of initiating ART in accordance to BHIVA guidelines at a dual-site HIV service in NHS 
Grampian. 
Methods – A retrospective case notes review was conducted of ART-naïve HIV-positive patients 
attending clinics between January and December 2013. Data collection was performed using a proforma 
and imported into SPSS 23 for statistical analysis. 
Results – A total of 24 case notes were audited (GUM = 15, ID = 9). The median age of patients was 
39.5 years (IQR = 24.5 to 54.5), majority male (n = 21/24) and White Scottish (n = 11/24). Median 
baseline viral load was 77,355 copies/mL while the baseline CD4 count was 382.0. The mean time taken 
to achieve undetectable viral loads was 4.48 months (95% CI = 3.50 to 5.70). Overall, 70.8% of patients 
achieved undetectable viral load within 6 months (GUM = 11/15, ID = 6/9). Within 12 months, 95.8% of 
patients achieved undetectable viral loads (GUM = 15/15, ID = 8/9). A Kaplan-Meier survival analysis 
showed that patients with a baseline viral load of < 100,000 copies/mL achieved undetectable viral loads 
sooner compared to those with baseline viral load of > 100,000 copies/mL (3.43 months, 95% CI = 2.337 
to 3.663 vs. 6.11 months, 95% CI = 4.28 to 7.94; log-rank p = 0.013). 
Conclusions – Achieving undetectable viral loads in HIV patients on ART is a crucial outcome that can 
significantly improve morbidity and mortality, as well as reduce transmission risk. This audit has identified 
potential barriers to achieving undetectable viral loads within 6 months, including higher baseline viral 
load and CD4 count at initiation of ART.  
 
 
 
Time taken to reach undetectable viral loads in therapy-naïve 
HIV patients commencing ART  
 
 
Introduction 
 
The primary aim of antiretroviral therapy (ART) is the reduction of morbidity and 
mortality due to chronic HIV infection with minimal drug toxicity.1 Over the last 15 years, 
the tolerability of ART has improved significantly and patients on treatment now benefit 
from improved physical and psychological wellbeing. A further aim of ART is to reduce 
the risk of HIV transmission and it has been shown to prevent mother-to-child 
transmission and sexual transmission.2,3 
 
In the UK, the overwhelming majority of patients attending HIV services who receive 
ART experience long-term viral suppression and improved treatment outcomes. 
Additionally, the life expectancy of people living with HIV (PLWH) on ART has 
significantly improved, but remains approximately 13 years less than that of the UK 
population as a whole.4 A delay in treatment initiation has a significant impact, in that 
life expectancy is reduced by about 15 years if ART is started later than the current 
BHIVA guidelines recommend.4 
 
Central to ART is the suppression of viral load and this has been used as a means to 
measure disease burden in PLWH. This variable is used as a proxy for adherence as 
well as patient prognosis and risk of transmission. Therefore, achieving long-term viral 
suppression is a key outcome in ART. In this audit, we aim to assess the proportion of 
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patients achieving undetectable viral load (<50 HIV-1 RNA copies/ml) at 6 months and 
12 months, and whether this exceeds 75% in accordance with BHIVA Guidelines.1 
 
 
Standards Set for Audit 
 
1. Proportion of patients achieving undetectable viral loads within 6 months (<50 
copies/mL) - 75%. 
2. Proportion of patients with a CD4 <350 or <500 with an AIDS-defining illness 
initiated on ART – 75% 
3. Proportion of patients initiating ART containing two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus one of the following: a ritonavir-boosted 
protease inhibitor (PI/r), NNRTI, or an integrase inhibitor (INI) – 75% 
 
 
Methods 
 
A retrospective case note review was performed at the dual-site HIV service in NHS 
Grampian. All HIV-1-positive patients who were therapy-naïve and commencing ART 
between January 2013 and December 2013 were included. A data collection proforma 
was developed and used to extract relevant information which was then imported to 
SPSS 23 for statistical analysis.  
 
 
Results 
 
Patient demographics 
A total of 24 patients were commenced on ART in the audit time frame.  The age, sex, 
ethnicity, and clinic attended are illustrated in Table 1. 
 
Table 1: Socio-demographics of patients. 
Aspect n % 
Age 
26-35 
36-45 
≥46 
 
10 
7 
7 
 
41.6 
29.2 
29.2 
Sex 
Male 
Female 
 
21 
3 
 
87.5 
12.5 
Ethnicity 
White Scottish 
White British 
White – Other  
Asian 
Black African 
 
11 
4 
2 
2 
5 
 
45.8 
20.8 
16.7 
8.3 
8.3 
HIV clinic attended 
GUM 
Infection Unit (ID) 
 
15 
9 
 
62.5 
37.5 
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ART regimen 
 
The median (minimum, maximum) number of months between diagnosis and 
commencement of ART was 3.0 (1.0, 109.0). Figure 1 shows the ART regimens 
patients were started on. Two patients who commenced on darunavir/ritonavir and 
emtricitabine/tenofovir were subsequently switched to Eviplera to reduce tablet burden. 
One patient on Eviplera was switched to Truvada with raltegravir four months after 
initiation of ART. 
 
 
Figure 1 - ART regimen at initiation 
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HIV viral load and CD4 count 
 
 
Figure 2 - Survival plot showing proportions of patients with detectable viral load 
over time 
 
Figure 2 shows the overall Kaplan-Meier survival function for proportions of patients 
with detectable viral loads over time. The mean time to achieve undetectable viral load 
is 4.48 months (95% CI = 3.25 to 5.70). Patients with a baseline viral load of below 
100,000 copies/mL achieved undetectable viral loads earlier compared to patients with 
a baseline viral load of more than 100,000 copies/mL (3.43 months, 95% CI = 2.337 to 
3.663 vs. 6.11 months, 95% CI = 4.28 to 7.94). Conversely, those initiating ART at CD4 
below 350 achieved undetectable viral load later than those initiating at CD4 above 350  
(5.37 months, 95% CI = 3.57 to 7.16 vs. 4.14 months, 95% CI = 2.48 to 5.81) (Figure 
3).  
 
 
Figure 3 - Survival plot showing proportions of detectable patients over time. (A) 
Baseline viral load (Log-rank p =0.013); (B) Baseline CD4 count (Log-rank p = 
0.50) 
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Table 2 : Factors influencing proportion of patients achieving undetectable viral loads within 6 
months. 
 
In a Chi-Square analysis of variables measured in this audit, a borderline statistically 
significant difference was found between groups with variable time taken between 
diagnosis and commencement of ART (χ²=9.60, p=0.05).  There were no statistically 
significant differences in time taken to achieve undetectable viral loads in other factors 
such as age, sex, ethnicity, HIV clinic attended and ART regimen (Table 2).  
 
 
Discussion 
 
The results of this audit found that only 70.8% of patients commenced on ART 
achieved an undetectable viral load by 6 months, thus failing to achieve the targets 
recommended by BHIVA. However, it is known that variability between individuals can 
influence response to treatment, and the fact that 95.8% of patients attending HIV 
services in NHS Grampian eventually achieve undetectable viral loads within 12 
months is reassuring.  
 
 
Aspect 
Undetectable 
within 6 
months, n 
χ² 
 
p-
value 
Yes No 
Age 
26-35 
36-45 
46+ 
 
7 
5 
5 
 
3 
2 
2 
 
0.006 
 
0.99 
Sex 
Male 
Female 
 
14 
3 
 
7 
0 
 
1.41 
 
0.53 
Ethnicity 
White Scottish 
White British 
White - Other 
Asian 
Black African 
 
8 
3 
1 
2 
3 
 
3 
1 
1 
0 
2 
 
1.58 
 
0.81 
HIV clinic attended 
GUM 
Infection Unit 
 
11 
6 
 
4 
3 
 
0.12 
 
0.73 
Time taken between diagnosis and commencement of ART 
Less than 3 months 
3-6 months 
6-12 months 
1-2 years 
More than 2 years 
 
10 
1 
0 
1 
5 
 
3 
2 
2 
0 
0 
 
 
9.60 
 
 
0.05 
ART regimen 
Truvada & darunavir/ritonavir 
Atripla 
Eviplera 
 
5 
1 
11 
 
4 
2 
1 
 
5.58 
 
0.06 
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One of the limitations of this study is the small sample size that does not allow for 
conclusions to be made regarding factors that are likely to affect time to undetectable 
viral loads. Another limitation of the study is a failure to take into account Did Not 
Attend (DNA) rates as a contributing factor. In our study, it was clear that there were 
several patients who regularly failed to attend follow-up clinics, as there was missing 
data for viral load and CD4 measurements for some of the intervals measured. This 
was, however, not formally quantified. This should be an aspect of future audits or 
studies within the same area. Another limitation of the study is the poor quantification of 
adherence rates. ART adherence is a crucial factor in affecting the time taken to reach 
undetectable viral loads. It is also, unfortunately, a notoriously difficult parameter to 
measure in clinical practice as it relies on the information that patients volunteer, which 
may be grossly under- or over-estimated.  
 
 
Conclusions 
 
Achieving undetectable viral loads in HIV patients on ART is a crucial outcome that can 
significantly improve morbidity and mortality, as well as reduce transmission risk. This 
audit has identified potential barriers to achieving undetectable viral loads within 6 
months including higher baseline viral load and CD4 count. Furthermore, patients’ 
health-seeking behaviour, i.e. failure to attend follow-up appointments, and poor 
adherence to medication, may further precipitate treatment failure. These areas need to 
be addressed to ensure the target of 75% of patients with an undetectable viral load 
within 6 months of initiating ART can be achieved.  
 
 
Recommendations 
 
• Continue to encourage patients to attend follow-up as part of routine HIV care 
and explore different models of care in rural areas i.e. primary care taking viral 
load samples. 
• Adopt an early warning system for patients who are on ART but fail to attend 
appointments and/or fail to achieve undetectable viral loads by 6 months. 
• Consider closer monitoring of patients who start treatment with viral load 
>100,000 copies. 
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